CD47过表达在肠道非生发中心B细胞型弥漫大B细胞淋巴瘤中常见并与18q21获得相关
研究对238例弥漫大B细胞淋巴瘤(DLBCL)患者进行CD47、CD8、CD68免疫组化染色,并对37例进行靶向二代测序。肠道DLBCL的CD47高表达比例显著高于其他器官(41.4% vs 8.3%,P < .001),18q21获得/扩增者均为CD47高表达,肠道CD47高表达DLBCL局限于回肠末端至升结肠且均为非生发中心B细胞型。
要点
- 肠道DLBCL的CD47高表达比例为41.4%(24/58),其他器官为8.3%(15/180),P < .001。
- 18q21获得/扩增见于10/37例,且全部为CD47高表达。
- 肠道CD47高表达DLBCL局限于回肠末端至升结肠,且均为非生发中心B细胞型。
核心结论
- CD47高表达DLBCL与18q21获得/扩增密切相关,且在肠道中患病率高。
- 作者建议将CD47高表达DLBCL分为肠道型和非肠道型。
- 需进一步研究以评估此处所见特征组合是否可重复,以及是否足以将原发性肠道DLBCL视为独立的生物学实体。
研究设计与样本
- 对238例DLBCL患者进行CD47、CD8和CD68免疫组化染色,CD47按强度5级评分,CD8和CD68用QuPath软件定量评估。
- 对37例患者进行靶向大规模平行测序(二代测序)。
主要发现
- 按器官定量分析CD8和CD68,肠道DLBCL的细胞毒性T细胞浸润显著低于其他器官(P < .001)。
- CD47高表达组在肠道DLBCL中为24/58(41.4%),在其他器官DLBCL中为15/180(8.3%)(P < .001)。
- 18q21获得/扩增见于10/37例,且全部为CD47高表达。
- 肠道CD47高表达DLBCL发生于回肠末端至升结肠,且局限于非生发中心B细胞型。
- 生存分析中,非肠道CD47高表达DLBCL的预后差于肠道CD47高表达DLBCL(P = .025)。
临床怎么用
- 作者提出将CD47高表达DLBCL分为肠道型和非肠道型。
- 原文未据此给出临床推荐。
局限性
- 需进一步研究以评估此处所见特征组合是否可重复,以及是否足以将原发性肠道DLBCL视为独立的生物学实体。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The CD47/signal regulatory protein α pathway is an emerging immune checkpoint that is a new therapeutic target. We investigated CD47 expression in diffuse large B-cell lymphoma (DLBCL) of various subtypes and organs. Moreover, the relationship between CD47 expression and genetic alterations was analyzed using panel-based massively parallel sequencing (next-generation sequencing [NGS]). CD8, CD68, and CD47 immunohistochemical staining were performed on 238 patients with DLBCL. CD47 was scored according to intensity on a 5-level scale, and CD8 and CD68 were quantitatively evaluated using QuPath software. Panel-based NGS was performed in 37 patients. In CD8 and CD68 quantitative analyses by organs, intestinal DLBCL showed significantly lower cytotoxic T-cell infiltration than that in others (P < .001). The CD47-high group comprised 24 of 58 (41.4%) patients in the group with DLBCL from intestine and 15 of 180 (8.3%) patients in the group with DLBCL from other organs (P < .001). The 18q21 gain/amplification was found in 10 of 37 patients, and all of them were CD47-high. Intestinal CD47-high DLBCL occurred in terminal ileum to ascending colon and was restricted to nongerminal center B-cell type. In the survival analyses, the prognosis of nonintestinal CD47-high DLBCL was poorer than that of intestinal CD47-high DLBCL (P = .025). CD47-high DLBCL was closely associated with 18q21 gain/amplification and showed a high prevalence in intestine. We propose to classify CD47-high DLBCL into intestinal and nonintestinal types. Further studies are necessary to assess whether the constellation of features seen here is reproducible and sufficient to consider primary intestinal DLBCL as a distinct biological entity.
引用
- Cho J, Yoon SE, Kim SJ, et al. CD47 overexpression is common in intestinal non-GCB type diffuse large B-cell lymphoma and associated with 18q21 gain. Blood Adv. 2022. PMID: 35475881. doi:10.1182/bloodadvances.2021006305
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。